Fosun Pharma expands drug inclusion in national, commercial insurance catalogs

Effective January 1, 2026, multiple products from Shanghai Fosun Pharmaceutical Group and its subsidiaries will be listed in the 2025 National Medical Insurance Drug Catalog and the newly released Commercial Health Insurance Innovative Drug Catalog. This inclusion covers five newly added drugs, including Rivoceranib tablets and Apatinib mesylate capsules, and adjustments for two existing drugs, including added indications for Carfilzomib for injection.

The newly included or adjusted drugs generated combined sales of approximately 401 million yuan in 2024 and 892 million yuan in the first three quarters of 2025. These figures represent about 0.98% and 3.04% of the group’s total operating revenue during those respective periods.

Fosun Pharma anticipates these inclusions will enhance drug accessibility, reduce patient burden, and boost market promotion and sales, positively impacting future annual performance. However, the company cautions that actual sales performance is subject to factors such as demand, market competition, and sales channels, making the definitive impact on future operating results uncertain.